CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction
Jakub J. Regieli(Utrecht University), Pieter A. Doevendans(Central Military Hospital), Yolanda van der Graaf(SUNY Downstate Health Sciences University), Aeilko H. Zwinderman(Amsterdam Neuroscience), John J.P. Kastelein(QRx Pharma (United States)), Michiel L. Bots(Utrecht University), J. Wouter Jukema(Leiden University Medical Center), D. E. Grobbee(Radboud University Nijmegen), Jan Albert Kuivenhoven(University Medical Center Groningen)
Cited by 101
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews
|Journal of Clinical Epidemiology|2005|3.3k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k